5 results about "Hemolytic streptococcus" patented technology

The application discloses a bacillus licheniformis YL-001 with anti-inflammatory and antibacterial effects and an application thereof, and belongs to the technical field of biotechnology. The bacillus licheniformis YL-001 is separated from soil. The preservation number of the bacillus licheniformis is GDMCC No.66556. The metabolic product of the bacillus licheniformis YL-001 provided in the application has the abilities of significantly inhibiting secretion of inflammatory factors and growth of streptococcus pneumoniae and hemolytic streptococcus b, and can improve the total antioxidant capacity of serum. The strain has good biocompatibility and high safety, has important significance for development of anti-inflammatory or antibacterial drugs, health products and food, and is especially suitable for preparation of products with throat-protecting effects.

This invention belongs to the field of probiotic screening and application technology, specifically relating to a strain of *Lactobacillus paracasei* and its application in the prevention and treatment of colonic polyps and colon cancer. The *Lactobacillus paracasei*, named *Lactobacillus paracasei* V85, was deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, China, with accession number CCTCC NO: M2026124. The *Lactobacillus paracasei* V85 provided by this invention is sensitive to common antibiotics and has good biosafety; it possesses strong antioxidant function and a strong inhibitory effect on hemolytic streptococci; it can produce a strong agglutination effect with hemolytic streptococci, which is beneficial for inhibiting the colonization of hemolytic streptococci in the intestine, reducing the risk of colonic polyps and colon cancer caused by hemolytic streptococci, and can promote the proliferation of *Akkermansia myxophilus*. It can be used to prevent and treat colonic polyps and colon cancer caused by hemolytic streptococci, and has broad application prospects.

The invention relates to a flora prediction model for detecting premature delivery risk and a kit and application thereof. Through early-stage mNGS data collection and analysis, premature related strains are obtained, and through a large number of experimental screening and optimization, a set of optimal primer probe group is finally determined. The invention relates to a premature delivery risk calculation method, which comprises the following steps of: selecting 12 floras, namely lactobacillus crispatus, lactobacillus gasseri, lactobacillus inertus, lactobacillus jensenii, escherichia coli, enterococcus faecalis, enterobacter aerogenes, group B hemolytic streptococcus, ureaplasma parvum, chlamydia trachomatis, diplococcus gonorrhoeae and gardnerella vaginalis, and establishing a fluorescent quantitative PCR (Polymerase Chain Reaction) method and a premature delivery risk calculation model aiming at the detection of the 12 floras. Compared with an existing detection method, the method is simple, convenient, rapid, high in sensitivity and high in specificity, the false positive and false negative risk is reduced, and the purpose of batch detection is achieved. Clinically, the change of microbial flora in the reproductive system of a pregnant woman can be rapidly detected, corresponding treatment measures are taken, the risk of PTB occurrence is reduced, and the kit has a good application prospect.

The invention belongs to the technical field of antibiotic enzymes, and relates to a recombinant antibiotic enzyme PlyTC37 as well as a coding gene and application thereof. The amino acid sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 1, and the coding nucleotide sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 2. The recombinant antibiotic enzyme PlyTC37 disclosed by the invention has a wider bactericidal spectrum, so that the recombinant antibiotic enzyme PlyTC37 has a killing effect on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa and gram-positive bacteria such as staphylococcus aureus, streptococcus agalactiae and streptococcus hemolyticus, the MIC value of the recombinant antibiotic enzyme PlyTC37 to acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa is about 20 [mu] g / ml. Meanwhile, the recombinant antibiotic enzyme PlyTC37 enables the load of acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa to be reduced by 4-5 logarithmic units in the presence of NaCl with physiological concentration, so that the clinical application prospect of the recombinant antibiotic enzyme PlyTC37 is remarkably improved.

This invention belongs to the field of functional probiotic screening and application technology, specifically relating to a strain of *Lactobacillus plantarum* with the function of preventing and treating colon polyps and colon cancer, and its application. The *Lactobacillus plantarum* was deposited on January 15, 2026, at the China Center for Type Culture Collection (CCTCC), Wuhan University, China, with accession number CCTCC NO: M202026126. This strain can significantly inhibit the growth of hemolytic streptococci that induce colon polyps and colon cancer risk, and produces a flocculation effect with hemolytic streptococci, thus having important application value for the prevention and treatment of colon polyps and colon cancer.